Cabaletta Bio (CABA) Expected to Announce Quarterly Earnings on Thursday

Cabaletta Bio (NASDAQ:CABA) is projected to release its earnings data before the market opens on Thursday, March 20th. Analysts expect Cabaletta Bio to post earnings of ($0.66) per share for the quarter.

Cabaletta Bio Price Performance

CABA stock opened at $1.67 on Wednesday. Cabaletta Bio has a 1 year low of $1.59 and a 1 year high of $19.04. The firm has a market capitalization of $81.62 million, a P/E ratio of -0.78 and a beta of 2.58. The business’s 50-day moving average is $2.21 and its two-hundred day moving average is $3.14.

Analyst Upgrades and Downgrades

CABA has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Cabaletta Bio in a research note on Tuesday, February 18th. TD Cowen upgraded Cabaletta Bio to a “strong-buy” rating in a research report on Friday, November 29th. Wells Fargo & Company cut Cabaletta Bio from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $12.00 to $6.00 in a research report on Thursday, December 19th. Finally, Evercore ISI downgraded Cabaletta Bio from an “outperform” rating to an “inline” rating and dropped their price target for the stock from $15.00 to $6.00 in a research note on Friday, December 20th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $22.71.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.